Neuroscience is advancing faster than ever, and the biggest risk is the shift from science to commercial reality.
In this episode, Ginger Johnson, Senior Vice President at Lumanity, and Isabella (Bella) Giaquinta, Senior Consultant at Lumanity, discuss why commercial thinking needs to start early in neuroscience development. They explain why teams should define a target product profile before entering the clinic, covering the intended patient, the value the product is meant to deliver, and the evidence needed to support it. Ginger shares why the largest market is not always the right first indication, and why smart sequencing can build confidence in a mechanism, shape physician and payer perception, and set up future indications. Bella explores how psychedelics illustrate the challenge, from monitoring and site-of-care needs to access and reimbursement. They also unpack the evolving role of biomarkers and how precision psychiatry, supported by AI, could help match patients to the treatments most likely to work for them.
Tune in to learn how defining the patient, the meaningful benefit, and the real-world use case early can turn promising neuroscience into products that succeed!
Resources:
Connect with and follow Ginger Johnson on LinkedIn.
Connect with and follow Isabella Giaquinta on LinkedIn.
Learn more about Lumanity’s Neuroscience expertise.